Adam Green
Concepts (348)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 26 | 2026 | 429 | 6.870 |
Why?
| | Central Nervous System Neoplasms | 11 | 2025 | 177 | 5.180 |
Why?
| | Brain Neoplasms | 28 | 2026 | 1329 | 4.740 |
Why?
| | Neoplasms | 10 | 2025 | 2897 | 1.790 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2026 | 76 | 1.540 |
Why?
| | Ependymoma | 4 | 2023 | 176 | 1.530 |
Why?
| | Hydrazines | 3 | 2025 | 37 | 1.480 |
Why?
| | Triazoles | 3 | 2025 | 184 | 1.330 |
Why?
| | Child | 44 | 2026 | 22680 | 1.270 |
Why?
| | Glioblastoma | 5 | 2021 | 353 | 1.180 |
Why?
| | Extracorporeal Membrane Oxygenation | 5 | 2024 | 389 | 1.140 |
Why?
| | Registries | 5 | 2026 | 2410 | 1.100 |
Why?
| | Brain Stem Neoplasms | 4 | 2020 | 87 | 1.060 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2025 | 1150 | 1.050 |
Why?
| | Karyopherins | 2 | 2019 | 20 | 1.030 |
Why?
| | Socioeconomic Factors | 9 | 2025 | 1327 | 1.010 |
Why?
| | Insurance Coverage | 2 | 2019 | 243 | 0.930 |
Why?
| | Medical Oncology | 4 | 2024 | 338 | 0.930 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2019 | 207 | 0.920 |
Why?
| | Cerebellar Neoplasms | 3 | 2023 | 177 | 0.910 |
Why?
| | Antineoplastic Agents | 7 | 2020 | 2207 | 0.890 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2021 | 212 | 0.880 |
Why?
| | Patient Care Bundles | 1 | 2025 | 29 | 0.880 |
Why?
| | Protein-Arginine N-Methyltransferases | 1 | 2025 | 25 | 0.870 |
Why?
| | Rhabdomyosarcoma | 2 | 2024 | 64 | 0.830 |
Why?
| | Humans | 82 | 2026 | 145491 | 0.810 |
Why?
| | Healthcare Disparities | 2 | 2021 | 739 | 0.790 |
Why?
| | Wilms Tumor | 1 | 2024 | 88 | 0.750 |
Why?
| | Physicians, Primary Care | 1 | 2025 | 210 | 0.750 |
Why?
| | Germ-Line Mutation | 2 | 2021 | 176 | 0.730 |
Why?
| | Radiation | 2 | 2021 | 24 | 0.730 |
Why?
| | Cross Infection | 1 | 2025 | 264 | 0.730 |
Why?
| | raf Kinases | 1 | 2021 | 11 | 0.710 |
Why?
| | Biomarkers, Tumor | 4 | 2026 | 1321 | 0.700 |
Why?
| | Child, Preschool | 21 | 2026 | 11837 | 0.690 |
Why?
| | Sarcoma, Ewing | 1 | 2022 | 103 | 0.670 |
Why?
| | Infant | 16 | 2026 | 10064 | 0.670 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2021 | 13 | 0.660 |
Why?
| | Prognosis | 11 | 2026 | 4323 | 0.660 |
Why?
| | Cancer Care Facilities | 1 | 2021 | 48 | 0.660 |
Why?
| | Adolescent | 21 | 2026 | 22485 | 0.660 |
Why?
| | Neoplastic Stem Cells | 1 | 2025 | 409 | 0.650 |
Why?
| | Guideline Adherence | 1 | 2025 | 590 | 0.640 |
Why?
| | Bone Neoplasms | 1 | 2022 | 256 | 0.610 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 306 | 0.610 |
Why?
| | Meningeal Neoplasms | 1 | 2021 | 95 | 0.610 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 18 | 0.610 |
Why?
| | Male | 41 | 2026 | 72817 | 0.600 |
Why?
| | Kidney Neoplasms | 1 | 2024 | 416 | 0.590 |
Why?
| | Intensive Care Units | 2 | 2025 | 925 | 0.590 |
Why?
| | Gene Expression Regulation, Neoplastic | 9 | 2026 | 1439 | 0.590 |
Why?
| | Optic Nerve Neoplasms | 1 | 2019 | 12 | 0.580 |
Why?
| | Optic Chiasm | 1 | 2019 | 19 | 0.580 |
Why?
| | Retinoblastoma | 2 | 2016 | 42 | 0.580 |
Why?
| | Proto-Oncogene Proteins B-raf | 4 | 2025 | 224 | 0.580 |
Why?
| | Female | 43 | 2026 | 78763 | 0.580 |
Why?
| | Positron-Emission Tomography | 1 | 2021 | 343 | 0.580 |
Why?
| | Sepsis | 1 | 2025 | 661 | 0.560 |
Why?
| | Combined Modality Therapy | 7 | 2021 | 1269 | 0.550 |
Why?
| | Histones | 5 | 2026 | 663 | 0.550 |
Why?
| | Blood-Brain Barrier | 4 | 2024 | 157 | 0.550 |
Why?
| | Choroid Plexus Neoplasms | 1 | 2017 | 8 | 0.540 |
Why?
| | Craniopharyngioma | 1 | 2019 | 77 | 0.530 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2025 | 1965 | 0.530 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2017 | 15 | 0.530 |
Why?
| | Everolimus | 1 | 2017 | 113 | 0.510 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 1058 | 0.510 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2025 | 1417 | 0.510 |
Why?
| | Pituitary Neoplasms | 1 | 2019 | 190 | 0.500 |
Why?
| | Morpholines | 1 | 2017 | 129 | 0.500 |
Why?
| | Electric Stimulation Therapy | 1 | 2017 | 62 | 0.490 |
Why?
| | Neuroimaging | 1 | 2019 | 293 | 0.480 |
Why?
| | Retinal Neoplasms | 1 | 2016 | 37 | 0.470 |
Why?
| | Cell Line, Tumor | 11 | 2026 | 3537 | 0.470 |
Why?
| | Microbubbles | 3 | 2024 | 53 | 0.460 |
Why?
| | NF-kappa B | 1 | 2019 | 660 | 0.460 |
Why?
| | Carcinoma | 1 | 2017 | 224 | 0.460 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 436 | 0.450 |
Why?
| | Cohort Studies | 7 | 2025 | 5992 | 0.440 |
Why?
| | Oxadiazoles | 1 | 2014 | 37 | 0.430 |
Why?
| | Neutropenia | 1 | 2015 | 155 | 0.430 |
Why?
| | Genetic Variation | 1 | 2019 | 988 | 0.420 |
Why?
| | Retrospective Studies | 13 | 2026 | 17269 | 0.420 |
Why?
| | Neoplasm Grading | 3 | 2021 | 311 | 0.420 |
Why?
| | Virilism | 1 | 2014 | 6 | 0.420 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2014 | 120 | 0.420 |
Why?
| | Acrylamides | 1 | 2014 | 74 | 0.410 |
Why?
| | Thiazoles | 1 | 2014 | 139 | 0.410 |
Why?
| | Fathers | 1 | 2014 | 52 | 0.400 |
Why?
| | Young Adult | 11 | 2026 | 14192 | 0.400 |
Why?
| | Fever | 1 | 2015 | 317 | 0.400 |
Why?
| | SEER Program | 3 | 2020 | 229 | 0.400 |
Why?
| | Delayed Diagnosis | 1 | 2014 | 100 | 0.390 |
Why?
| | Rare Diseases | 1 | 2014 | 116 | 0.390 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2014 | 69 | 0.390 |
Why?
| | Adrenocortical Carcinoma | 1 | 2014 | 71 | 0.390 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2020 | 431 | 0.380 |
Why?
| | Microglia | 2 | 2026 | 275 | 0.370 |
Why?
| | Pyrimidinones | 2 | 2025 | 125 | 0.370 |
Why?
| | DNA Copy Number Variations | 2 | 2023 | 184 | 0.340 |
Why?
| | Mutation | 8 | 2026 | 4093 | 0.330 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2025 | 296 | 0.330 |
Why?
| | United States | 11 | 2024 | 16115 | 0.330 |
Why?
| | Social Determinants of Health | 2 | 2025 | 308 | 0.320 |
Why?
| | Testosterone | 1 | 2014 | 413 | 0.310 |
Why?
| | Anemia, Sickle Cell | 2 | 2025 | 318 | 0.310 |
Why?
| | Cell Proliferation | 5 | 2025 | 2499 | 0.300 |
Why?
| | Medulloblastoma | 2 | 2023 | 215 | 0.300 |
Why?
| | Tumor Microenvironment | 2 | 2025 | 737 | 0.290 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2021 | 191 | 0.290 |
Why?
| | Social Class | 3 | 2023 | 265 | 0.290 |
Why?
| | Respiratory Insufficiency | 2 | 2023 | 325 | 0.290 |
Why?
| | Infant, Newborn | 6 | 2020 | 6437 | 0.280 |
Why?
| | Astrocytoma | 3 | 2025 | 130 | 0.280 |
Why?
| | Archaeology | 2 | 2025 | 39 | 0.270 |
Why?
| | Treatment Outcome | 8 | 2026 | 11831 | 0.260 |
Why?
| | Proto-Oncogene Proteins | 2 | 2020 | 620 | 0.250 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 1769 | 0.240 |
Why?
| | Teratoma | 2 | 2023 | 124 | 0.240 |
Why?
| | Quality Improvement | 1 | 2015 | 1294 | 0.240 |
Why?
| | Rhabdoid Tumor | 2 | 2023 | 102 | 0.240 |
Why?
| | Babesiosis | 1 | 2026 | 4 | 0.240 |
Why?
| | Survival Analysis | 2 | 2020 | 1374 | 0.240 |
Why?
| | Disease Progression | 2 | 2024 | 2862 | 0.240 |
Why?
| | Neurocognitive Disorders | 1 | 2025 | 33 | 0.230 |
Why?
| | Autophagy | 2 | 2019 | 288 | 0.230 |
Why?
| | 12E7 Antigen | 1 | 2025 | 10 | 0.230 |
Why?
| | Prospective Studies | 4 | 2024 | 8039 | 0.230 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2025 | 53 | 0.230 |
Why?
| | DNA Methylation | 4 | 2026 | 667 | 0.230 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2025 | 49 | 0.230 |
Why?
| | Follow-Up Studies | 4 | 2026 | 5426 | 0.220 |
Why?
| | Ganglioglioma | 1 | 2025 | 34 | 0.220 |
Why?
| | Neoplasm Staging | 2 | 2026 | 1468 | 0.220 |
Why?
| | Animals | 14 | 2026 | 38141 | 0.220 |
Why?
| | Sonication | 1 | 2024 | 12 | 0.220 |
Why?
| | Mice | 10 | 2025 | 18338 | 0.220 |
Why?
| | Maximum Tolerated Dose | 1 | 2025 | 211 | 0.220 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1953 | 0.210 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2025 | 929 | 0.210 |
Why?
| | Middle Aged | 10 | 2026 | 36176 | 0.210 |
Why?
| | Pyridones | 1 | 2025 | 208 | 0.200 |
Why?
| | Erythrocyte Transfusion | 1 | 2026 | 227 | 0.200 |
Why?
| | Adult | 9 | 2026 | 40707 | 0.200 |
Why?
| | Hospital Mortality | 2 | 2026 | 1044 | 0.200 |
Why?
| | Postoperative Care | 1 | 2025 | 286 | 0.200 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2023 | 60 | 0.190 |
Why?
| | Perioperative Care | 1 | 2025 | 232 | 0.190 |
Why?
| | Biology | 1 | 2024 | 89 | 0.190 |
Why?
| | Nerve Net | 1 | 2026 | 284 | 0.190 |
Why?
| | Carcinogenesis | 1 | 2025 | 227 | 0.190 |
Why?
| | Case-Control Studies | 2 | 2023 | 3619 | 0.180 |
Why?
| | Hodgkin Disease | 1 | 2024 | 171 | 0.180 |
Why?
| | Patient Selection | 2 | 2024 | 742 | 0.180 |
Why?
| | Brain | 5 | 2026 | 2944 | 0.180 |
Why?
| | Cerebrospinal Fluid | 1 | 2022 | 88 | 0.180 |
Why?
| | Preimplantation Diagnosis | 1 | 2021 | 6 | 0.180 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2021 | 14 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2030 | 0.180 |
Why?
| | Extracellular Matrix | 1 | 2026 | 562 | 0.170 |
Why?
| | Pons | 2 | 2026 | 33 | 0.170 |
Why?
| | Protein Kinase Inhibitors | 2 | 2025 | 980 | 0.170 |
Why?
| | Gene Ontology | 1 | 2021 | 54 | 0.170 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 72 | 0.170 |
Why?
| | Magnetic Resonance Imaging | 5 | 2024 | 3897 | 0.170 |
Why?
| | Time Factors | 3 | 2024 | 7171 | 0.170 |
Why?
| | Cause of Death | 1 | 2023 | 469 | 0.170 |
Why?
| | Gene Amplification | 1 | 2021 | 120 | 0.170 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2021 | 53 | 0.170 |
Why?
| | Respiration, Artificial | 2 | 2023 | 712 | 0.170 |
Why?
| | Epigenesis, Genetic | 2 | 2023 | 672 | 0.170 |
Why?
| | Mentors | 1 | 2023 | 218 | 0.170 |
Why?
| | Infusions, Intra-Arterial | 1 | 2021 | 61 | 0.170 |
Why?
| | Fertilization in Vitro | 1 | 2021 | 93 | 0.170 |
Why?
| | Aged | 7 | 2026 | 26125 | 0.160 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 168 | 0.160 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2024 | 338 | 0.160 |
Why?
| | Geography | 1 | 2021 | 204 | 0.160 |
Why?
| | Leukocytes | 1 | 2022 | 295 | 0.160 |
Why?
| | Cell Differentiation | 3 | 2020 | 2045 | 0.160 |
Why?
| | Cell Survival | 3 | 2019 | 1094 | 0.160 |
Why?
| | Zinc | 1 | 2023 | 297 | 0.160 |
Why?
| | Benzamides | 2 | 2019 | 224 | 0.160 |
Why?
| | Cyclophosphamide | 1 | 2021 | 266 | 0.160 |
Why?
| | Receptor, EphB4 | 1 | 2020 | 33 | 0.160 |
Why?
| | Ephrin-B2 | 1 | 2020 | 45 | 0.160 |
Why?
| | Heart Arrest | 1 | 2024 | 409 | 0.160 |
Why?
| | Multifactorial Inheritance | 1 | 2021 | 190 | 0.160 |
Why?
| | Computer Simulation | 2 | 2021 | 1026 | 0.160 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2020 | 66 | 0.160 |
Why?
| | Genes, myc | 1 | 2020 | 51 | 0.160 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 39 | 0.150 |
Why?
| | Recurrence | 1 | 2023 | 1142 | 0.150 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2019 | 14 | 0.150 |
Why?
| | Immunophenotyping | 1 | 2021 | 320 | 0.150 |
Why?
| | Pedigree | 1 | 2021 | 515 | 0.150 |
Why?
| | Eye Enucleation | 2 | 2016 | 14 | 0.150 |
Why?
| | Critical Care | 1 | 2025 | 703 | 0.150 |
Why?
| | Critical Illness | 2 | 2023 | 901 | 0.150 |
Why?
| | Age Distribution | 1 | 2020 | 403 | 0.150 |
Why?
| | Sex Distribution | 1 | 2020 | 387 | 0.150 |
Why?
| | Sirolimus | 1 | 2021 | 280 | 0.150 |
Why?
| | Protein Domains | 1 | 2021 | 314 | 0.140 |
Why?
| | Models, Genetic | 1 | 2021 | 531 | 0.140 |
Why?
| | Transcriptome | 2 | 2025 | 1038 | 0.140 |
Why?
| | Influenza Vaccines | 1 | 2023 | 533 | 0.140 |
Why?
| | Deoxycytidine | 1 | 2020 | 222 | 0.140 |
Why?
| | Blood Coagulation Disorders | 1 | 2021 | 198 | 0.140 |
Why?
| | Genetic Testing | 1 | 2021 | 480 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2024 | 1755 | 0.130 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1511 | 0.130 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 6070 | 0.130 |
Why?
| | Crohn Disease | 1 | 2021 | 259 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 2 | 2019 | 2772 | 0.130 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 426 | 0.130 |
Why?
| | Genes, p53 | 1 | 2017 | 67 | 0.130 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 62 | 0.130 |
Why?
| | Pyrimidines | 2 | 2019 | 520 | 0.130 |
Why?
| | Schizophrenia | 1 | 2021 | 444 | 0.130 |
Why?
| | Transfection | 1 | 2019 | 925 | 0.130 |
Why?
| | Phosphorylation | 2 | 2020 | 1707 | 0.130 |
Why?
| | Risk Factors | 4 | 2025 | 10874 | 0.130 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 470 | 0.120 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 138 | 0.120 |
Why?
| | Chloroquine | 1 | 2017 | 54 | 0.120 |
Why?
| | Epigenomics | 3 | 2023 | 112 | 0.120 |
Why?
| | Prevalence | 1 | 2024 | 2855 | 0.120 |
Why?
| | Macrophages | 1 | 2024 | 1509 | 0.120 |
Why?
| | Mortality | 1 | 2019 | 379 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 553 | 0.120 |
Why?
| | Radiotherapy | 1 | 2017 | 205 | 0.120 |
Why?
| | Inflammation | 2 | 2024 | 2883 | 0.120 |
Why?
| | Pyrazoles | 1 | 2020 | 517 | 0.120 |
Why?
| | Cell Cycle Proteins | 1 | 2020 | 631 | 0.120 |
Why?
| | Immunotherapy | 1 | 2021 | 667 | 0.120 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 439 | 0.110 |
Why?
| | Phenotype | 1 | 2024 | 3157 | 0.110 |
Why?
| | Apoptosis | 3 | 2025 | 2411 | 0.110 |
Why?
| | Anticoagulants | 1 | 2021 | 750 | 0.110 |
Why?
| | Cell Culture Techniques | 1 | 2017 | 373 | 0.110 |
Why?
| | Macaca fascicularis | 1 | 2014 | 70 | 0.110 |
Why?
| | Primary Health Care | 1 | 2025 | 1734 | 0.110 |
Why?
| | Cell Cycle | 1 | 2017 | 595 | 0.110 |
Why?
| | Adrenalectomy | 1 | 2014 | 68 | 0.100 |
Why?
| | Cell Cycle Checkpoints | 1 | 2014 | 98 | 0.100 |
Why?
| | Mutism | 1 | 2014 | 7 | 0.100 |
Why?
| | Administration, Cutaneous | 1 | 2014 | 126 | 0.100 |
Why?
| | Stroke | 1 | 2023 | 1272 | 0.100 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2021 | 686 | 0.100 |
Why?
| | Insurance, Health | 1 | 2016 | 308 | 0.100 |
Why?
| | Chemoradiotherapy | 1 | 2015 | 239 | 0.100 |
Why?
| | Infratentorial Neoplasms | 1 | 2014 | 71 | 0.100 |
Why?
| | Precision Medicine | 1 | 2017 | 456 | 0.100 |
Why?
| | Indoles | 1 | 2017 | 508 | 0.090 |
Why?
| | Sulfonamides | 1 | 2017 | 581 | 0.090 |
Why?
| | Diagnostic Errors | 1 | 2014 | 179 | 0.090 |
Why?
| | Aminopyridines | 2 | 2025 | 129 | 0.090 |
Why?
| | Hydrocortisone | 1 | 2014 | 298 | 0.090 |
Why?
| | Neoplasm Invasiveness | 2 | 2026 | 505 | 0.090 |
Why?
| | Dexamethasone | 1 | 2014 | 366 | 0.090 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2017 | 881 | 0.080 |
Why?
| | Drug Synergism | 2 | 2025 | 353 | 0.080 |
Why?
| | Drug Delivery Systems | 2 | 2024 | 382 | 0.080 |
Why?
| | Weight Gain | 1 | 2014 | 557 | 0.080 |
Why?
| | Survival Rate | 3 | 2021 | 2093 | 0.080 |
Why?
| | Aging | 1 | 2020 | 1940 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 1 | 2014 | 2526 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2014 | 775 | 0.070 |
Why?
| | Electronic Health Records | 1 | 2015 | 1187 | 0.060 |
Why?
| | Parasitemia | 1 | 2026 | 15 | 0.060 |
Why?
| | Longitudinal Studies | 1 | 2014 | 2950 | 0.060 |
Why?
| | Chromatin | 2 | 2020 | 555 | 0.060 |
Why?
| | Fibronectins | 1 | 2026 | 132 | 0.060 |
Why?
| | History, Ancient | 1 | 2025 | 55 | 0.060 |
Why?
| | Receptors, CCR1 | 1 | 2024 | 4 | 0.050 |
Why?
| | Ultrasonic Waves | 1 | 2024 | 9 | 0.050 |
Why?
| | Thalamus | 1 | 2026 | 127 | 0.050 |
Why?
| | Purines | 1 | 2025 | 187 | 0.050 |
Why?
| | United Kingdom | 1 | 2025 | 339 | 0.050 |
Why?
| | Receptors, CCR5 | 1 | 2024 | 60 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2025 | 4559 | 0.050 |
Why?
| | Agriculture | 1 | 2025 | 103 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2021 | 2129 | 0.050 |
Why?
| | Histology | 1 | 2023 | 4 | 0.050 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2023 | 19 | 0.050 |
Why?
| | Caco-2 Cells | 1 | 2023 | 79 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 5989 | 0.050 |
Why?
| | Myeloid Cells | 1 | 2024 | 146 | 0.050 |
Why?
| | SMARCB1 Protein | 1 | 2023 | 34 | 0.050 |
Why?
| | Particle Size | 1 | 2024 | 402 | 0.050 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2023 | 80 | 0.050 |
Why?
| | Cytosol | 1 | 2023 | 214 | 0.050 |
Why?
| | Research Personnel | 1 | 2024 | 187 | 0.050 |
Why?
| | Career Choice | 1 | 2024 | 235 | 0.050 |
Why?
| | Synapses | 1 | 2026 | 438 | 0.050 |
Why?
| | Organic Chemicals | 1 | 2023 | 126 | 0.050 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2008 | 700 | 0.040 |
Why?
| | Mitosis | 1 | 2023 | 200 | 0.040 |
Why?
| | DNA Helicases | 1 | 2023 | 141 | 0.040 |
Why?
| | Immunization | 1 | 2023 | 375 | 0.040 |
Why?
| | Cerebellum | 1 | 2023 | 224 | 0.040 |
Why?
| | Contrast Media | 1 | 2024 | 500 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 667 | 0.040 |
Why?
| | Chromosome Deletion | 1 | 2021 | 126 | 0.040 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2021 | 70 | 0.040 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2021 | 68 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 443 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2025 | 1139 | 0.040 |
Why?
| | Gene Rearrangement | 1 | 2021 | 156 | 0.040 |
Why?
| | Patient Readmission | 1 | 2026 | 769 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 517 | 0.040 |
Why?
| | Intubation, Intratracheal | 1 | 2023 | 326 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2023 | 499 | 0.040 |
Why?
| | Length of Stay | 1 | 2025 | 1348 | 0.040 |
Why?
| | Hospitals | 1 | 2024 | 732 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2025 | 862 | 0.040 |
Why?
| | Genome, Human | 1 | 2021 | 420 | 0.040 |
Why?
| | Tumor Suppressor Proteins | 1 | 2021 | 320 | 0.040 |
Why?
| | Administration, Oral | 1 | 2021 | 863 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 974 | 0.040 |
Why?
| | Sex Factors | 1 | 2024 | 2110 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 883 | 0.030 |
Why?
| | Mice, Nude | 1 | 2020 | 678 | 0.030 |
Why?
| | Lysine | 1 | 2020 | 272 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2023 | 743 | 0.030 |
Why?
| | Health Personnel | 1 | 2024 | 750 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2026 | 2945 | 0.030 |
Why?
| | RNA-Binding Proteins | 1 | 2021 | 461 | 0.030 |
Why?
| | Blotting, Western | 1 | 2019 | 1162 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 821 | 0.030 |
Why?
| | Venous Thromboembolism | 1 | 2021 | 327 | 0.030 |
Why?
| | Pediatrics | 1 | 2024 | 1121 | 0.030 |
Why?
| | Pandemics | 1 | 2024 | 1706 | 0.030 |
Why?
| | Cell Movement | 1 | 2020 | 961 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1156 | 0.030 |
Why?
| | Hemorrhage | 1 | 2021 | 826 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1733 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1423 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1468 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2189 | 0.030 |
Why?
| | Hospitalization | 1 | 2024 | 2458 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2024 | 5891 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2355 | 0.020 |
Why?
| | Health Status Disparities | 1 | 2015 | 321 | 0.020 |
Why?
| | Risk Assessment | 1 | 2021 | 3759 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 7197 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 5202 | 0.020 |
Why?
| | Transplantation, Autologous | 1 | 2008 | 298 | 0.020 |
Why?
|
|
Green's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|